These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 32272396)

  • 21. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
    Somasundaram R; Choraria A; Antonysamy M
    Int Immunopharmacol; 2020 Aug; 85():106654. PubMed ID: 32512271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
    Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
    Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
    Morabito CJ; Gangadharan B
    Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
    [No Abstract]   [Full Text] [Related]  

  • 24. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
    Díez JM; Romero C; Gajardo R
    Immunotherapy; 2020 Jun; 12(8):571-576. PubMed ID: 32397847
    [No Abstract]   [Full Text] [Related]  

  • 25. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
    İnandıklıoğlu N; Akkoc T
    Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
    Sariol A; Perlman S
    Immunity; 2020 Aug; 53(2):248-263. PubMed ID: 32717182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.
    Zimmermann P; Curtis N
    Pediatr Infect Dis J; 2020 May; 39(5):355-368. PubMed ID: 32310621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines for COVID-19: The current state of play.
    Koirala A; Joo YJ; Khatami A; Chiu C; Britton PN
    Paediatr Respir Rev; 2020 Sep; 35():43-49. PubMed ID: 32653463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronavirus vaccine-associated lung immunopathology-what is the significance?
    Bottazzi ME; Strych U; Hotez PJ; Corry DB
    Microbes Infect; 2020 Oct; 22(9):403-404. PubMed ID: 32599077
    [No Abstract]   [Full Text] [Related]  

  • 31. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
    Mansourabadi AH; Sadeghalvad M; Mohammadi-Motlagh HR; Rezaei N
    Life Sci; 2020 Oct; 258():118185. PubMed ID: 32750438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Audio Interview: Capitalizing on Immune Responses to Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
    [No Abstract]   [Full Text] [Related]  

  • 34. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019].
    Yan CX; Li J; Shen X; Luo L; Li Y; Li MY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 51(2):139-145. PubMed ID: 32220178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal Antibodies for Prevention and Treatment of COVID-19.
    Marovich M; Mascola JR; Cohen MS
    JAMA; 2020 Jul; 324(2):131-132. PubMed ID: 32539093
    [No Abstract]   [Full Text] [Related]  

  • 38. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conserved HLA binding peptides from five non-structural proteins of SARS-CoV-2-An in silico glance.
    Marchan J
    Hum Immunol; 2020; 81(10-11):588-595. PubMed ID: 32888767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapeutic approaches to curtail COVID-19.
    Owji H; Negahdaripour M; Hajighahramani N
    Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.